Development of stabilised mixtures of fluorescentally labelled antibodies in a single test pack for flow cytometry (Q12098): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: summary (P836): The objective of the project is to increase the own R & D capacities of EXBIO Praha, a.s. in the area of stabilised mixtures of fluorescent antibody in single-test packages for flow cytometry. The extension of the VIK will strengthen the company’s position in world trade in monoclonal antibodies, their derivatives and diagnostic kits for clinical diagnosis in the health sector and allow for the further expansion and diversification of products...) |
(Created claim: summary (P836): The aim of the project is to increase the R & D capacity of Exbio Praha, a.s. in the area of stabilised mixtures of fluorescence-labelled antibodies in a single-test packaging for flow cytometry. The expansion of VIK will strengthen the company’s position in the world trade in monoclonal antibodies, their derivatives and diagnostic kits for clinical diagnosis in health care and will allow further expansion and diversification of products mainly...) |
||||||||||||||
| Property / summary | |||||||||||||||
The aim of the project is to increase the R & D capacity of Exbio Praha, a.s. in the area of stabilised mixtures of fluorescence-labelled antibodies in a single-test packaging for flow cytometry. The expansion of VIK will strengthen the company’s position in the world trade in monoclonal antibodies, their derivatives and diagnostic kits for clinical diagnosis in health care and will allow further expansion and diversification of products mainly into medical diagnostics. a. (English) | |||||||||||||||
| Property / summary: The aim of the project is to increase the R & D capacity of Exbio Praha, a.s. in the area of stabilised mixtures of fluorescence-labelled antibodies in a single-test packaging for flow cytometry. The expansion of VIK will strengthen the company’s position in the world trade in monoclonal antibodies, their derivatives and diagnostic kits for clinical diagnosis in health care and will allow further expansion and diversification of products mainly into medical diagnostics. a. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The aim of the project is to increase the R & D capacity of Exbio Praha, a.s. in the area of stabilised mixtures of fluorescence-labelled antibodies in a single-test packaging for flow cytometry. The expansion of VIK will strengthen the company’s position in the world trade in monoclonal antibodies, their derivatives and diagnostic kits for clinical diagnosis in health care and will allow further expansion and diversification of products mainly into medical diagnostics. a. (English) / qualifier | |||||||||||||||
point in time: 22 October 2020
| |||||||||||||||
Revision as of 15:11, 22 October 2020
Project in Czech Republic financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of stabilised mixtures of fluorescentally labelled antibodies in a single test pack for flow cytometry |
Project in Czech Republic financed by DG Regio |
Statements
11,165,000.0 Czech koruna
0 references
22,330,000.0 Czech koruna
0 references
50 percent
0 references
31 December 2020
0 references
EXBIO Praha, a.s.
0 references
49°59'0.49"N, 14°30'9.11"E
0 references
25250
0 references
Cílem projektu je zvýšení kapacit vlastního VaV společnosti EXBIO Praha, a.s. v oblasti stabilizovaných směsí fluorescenčně značených protilátek v jednotestovém balení pro průtokovou cytometrii. Rozšíření VIK posílí postavení společnosti na světovém obchodu s monoklonálními protilátkami, jejich deriváty a diagnostickými soupravami pro klinickou diagnostiku ve zdravotnictví a umožní další rozšíření a diversifikaci produktů především do zdravotnické diagnostiky. a. (Czech)
0 references
The aim of the project is to increase the R & D capacity of Exbio Praha, a.s. in the area of stabilised mixtures of fluorescence-labelled antibodies in a single-test packaging for flow cytometry. The expansion of VIK will strengthen the company’s position in the world trade in monoclonal antibodies, their derivatives and diagnostic kits for clinical diagnosis in health care and will allow further expansion and diversification of products mainly into medical diagnostics. a. (English)
22 October 2020
0 references
Identifiers
CZ.01.1.02/0.0/0.0/17_165/0015522
0 references